Annual Report on Form 10-K for the fiscal year ended December 31, 2023 (Bristol-Myers Squibb Company) (2024)

Government Record · Bristol-Myers Squibb Company · February 13, 2024

Bristol-Myers Squibb Company, 2024-02-13: BMS's 10-K reports Revlimid revenues of $12.821 billion (2021), $9.978 billion (2022) and $6.097 billion (2023), and its glossary states Celgene was acquired by BMS on November 20, 2019.

Revlimid 6,097 9,978 12,821

Item 7 – product revenues table (table row)

Bristol-Myers Squibb Company, 2024-02-13: BMS's 10-K reports Revlimid revenues of $12.821 billion (2021), $9.978 billion (2022) and $6.097 billion (2023), and its glossary states Celgene was acquired by BMS on November 20, 2019. Company filing: no external funder; BMS (which acquired Celgene) sells Revlimid. No comparator. EDGAR serves HTM only, so pdf_url is empty. CORRECTION: the book's 'nearly $12 billion in 2022' matches 2021 ($12.821B); 2022 was $9.978B, a 22% fall driven by generic erosion. The 'Celgene's drug' and 'BMS bought Celgene in 2019' elements are correct – the 10-K glossary reads 'Celgene Corporation acquired by BMS on November 20, 2019'.